Results 81 to 90 of about 4,025 (198)

An Evaluation of Fidaxomicin Use in a Community Health System

, 2014
Background: Fidaxomicin is a narrow spectrum, non-absorbed antibiotic that is indicated for the treatment of Clostridium difficile infection (CDI).
Boyd, Sarah
core   +1 more source

Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi‐Institutional Experience

Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.
ABSTRACT Clostridioides difficile infection (CDI) represents a significant health risk to pediatric stem cell transplant (SCT) patients. In these patients, recurrent CDI is common, requiring prolonged antibiotic usage and increased hospitalization. Bezlotoxumab, a monoclonal antibody that targets the toxin responsible for CDI, has demonstrated efficacy
Aaron E. Fan, Shaikha Alqahtani, Natalie Dailey Garnes, Priti Tewari, Demetrios Petropoulos, Sajad Khazal, Kris Mahadeo, Paige DePriest, Irtiza N. Sheikh   +8 more
wiley   +1 more source

Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis

Antibiotics, 2017
Lipiarmycin A3 and tiacumicin B possess the same chemical structure and have been considered identical till recently, when some authors have suggested the possibility of a minor difference between the chemical structures of the two antibiotics.
Stefano Serra, Luciana Malpezzi, Angelo Bedeschi, Claudio Fuganti, Piera Fonte   +4 more
doaj   +1 more source

Caring at the transition: success and financial barriers of fidaxomicin discharge prescriptions for inpatients with Clostridioides difficile infection

Antimicrobial Stewardship & Healthcare Epidemiology
This retrospective cohort study evaluated the proportion of inpatients initiated and successfully discharged on fidaxomicin for Clostridioides difficile infection.
Ellen Earle, Jigar Mehta, Alexis Blecher, Matthew Shou Lun Lee   +3 more
doaj   +1 more source

Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates

, 2015
The aim of this study was to investigate in vitro activities of fidaxomicin and other antibiotics against 188 Clostridium difficile strains collected from different centers of Hungary. C.
Nagy Erzsébet, Zsoldiné Urbán Edit, Eitel Zsuzsa, Terhes Gabriella, Sóki József   +4 more
core   +1 more source

Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study

Heliyon
Objectives: The main aim of this study was to compare the clinical outcomes of patients attended in our area with Clostridioides difficile infection (CDI) (sustained cure, recurrence or death) in relation to treatment to normal or hypervirulent C ...
Marcos Hernando-Gozalo, Carlos Rescalvo-Casas, Laura Seijas-Pereda, Juan Cuadros-González, Ramón Pérez-Tanoira   +4 more
doaj   +1 more source

Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections:a meta-analysis and indirect treatment comparison

, 2014
Objectives To evaluate the efficacy of fidaxomicin treatment, which has a limited effect on the normal gut flora, compared with vancomycin and metronidazole treatment in Clostridium difficile infections (CDIs). Methods A systematic literature review was
Cornely, Oliver A., Odufowora-Sita, Olatunji, Odeyemi, Isaac A. O., Retsa, Peny, Nathwani, Dilip, Ivanescu, Cristina   +5 more
core   +1 more source

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. [PDF]

, 2012
peer reviewedTwo recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences.
Stoesser, Nicole E., A Sarah Walker (9251970), Kean, Y, Walker, A Sarah, Stoesser, Nicole E, Weiss, K, Miller, MA, Sherwood L Gorbach (16235663), Peto, Timothy E A, Stoesser, NE, Mark A Miller (15241241), Peto, Timothy E. A., Angus, Brian J, Miller, Mark A., Gorbach, Sherwood L, Walker, AS, Crook, Derrick W., Derrick W Crook (9552821), Yin Kean (16235648), Young, BC, Roberto Esposito (139969), Bernadette C Young (16235657), Gorbach, Sherwood L., Angus, Brian, Louie, TJ, Jacobs, Frédérique, Crook, DW, Angus, BJ, Brian J Angus (16235660), Cornely, Oliver A, Kean, Yin, Crook, Derrick W, Walker, Ann, Nicole E Stoesser (16235654), Timothy E A Peto (16039838), Young, Bernadette C, Martin Llewelyn (4461757), Cornely, Oliver A., et al the Optimer Study 003/004 teams (16235666), Peto, TE, Esposito, R, Louie, Thomas J, Walker, A. Sarah, Karl Weiss (471420), Esposito, Roberto, Miller, Mark A, Weiss, Karl, Young, Bernadette C., Louie, Thomas J., Angus, Brian J., Thomas J Louie (16235651), Gorbach, SL, Oliver A Cornely (16234868), Cornely, OA   +53 more
core   +1 more source

Clostridioides difficile: Modern Approaches in Pathogenesis, Diagnosis, Treatment, Prevention, Emerging Perspectives and Health Economics

Gastroenterology Insights
Introduction: Clostridioides difficile (C. difficile) is a major cause of antibiotic-associated diarrhea and healthcare-associated infections, with rising global incidence and severity due to the emergence of hypervirulent strains.
Nikoletta T. Karavasili, Konstantinos H. Katsanos, Ioanna Nefeli Mastorogianni, Maria Veatriki Christodoulou, Georgios Manomenidis, Dimitrios Kosmidis, Anastasios Tzenalis, Albani Eleni, Stavroula Tsiara, Dimitrios K. Christodoulou   +9 more
doaj   +1 more source

Fidaxomicin gyártásközi- és végtermék hatóanyagtartalmának meghatározására szolgáló analitikai módszer validálása

, 2015
Fidaxomicin hatóanyagtartalmának meghatározására szolgáló HPLC-s módszert validáltam. Célom az volt, hogy a módszert a szabványműveleti előírásokban foglaltaknak megfelelően ellenőrizzem le, és bebizonyítsam, hogy a módszer biztonságosan használható ...
Drengubák, Diána
core